Find and Pitch Jounalists, Get Your Story Covered

Tags: leptin plasma alzheimer disease alzheimer's disease amyloid

	Profile	Recent Articles on Subject
1	Michael DePeau-Wilson MedPage Today Enterprise Reporter. AI in Healthcare focus. Journalism alum. Not specified healthcareartificial intelligencejournalismpodcasting	Managing AI Risks in Healthcare; GPT-4's Clinical Biases; DIY AI Clinic - 5 months ago
2	Charles Bankhead MedPage Today	Another CAR-T Warning; 'Sweet' Cancer Test; 'Molecular Jackhammer' Blows Up Cancer - 5 months ago Clinical Challenges: Test Your Knowledge on Cancer and Immunotherapy - 6 months ago Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia - 6 months ago Another Win for Biomarker-Driven Thromboprophylaxis for Patients With Cancer - 8 months ago
3	Flora Graham Nature	Daily briefing: Criticism hits nematode cancer tests - 5 months ago
4	Susan Kelly MedTech Dive Med tech founder, slack parent. Med techinnovationbeach	Roundup: Illumina’s long goodbye to cancer test maker Grail - 5 months ago Invitae test for hereditary cancers gains FDA de novo nod - 7 months ago
5	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT Virtual Event \| Cancer’s Breakthrough Engine - 5 months ago STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation - 6 months ago
6	Alana Hippensteele, Managing Editor Pharmacy Times	Use of Recurrence Score Combined With Clinical, Genetic Factors Improves Prognostic Ability in HR+/ HER2– Early Breast Cancer - 5 months ago
7	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 5 months ago Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO - 7 months ago Want a biotech buyout? Target cancer - 7 months ago
8	Nick Paul Taylor MedTech Dive Top 5 Mario Kart Player. Gaming	Freenome starts 20,000-subject study of lung cancer blood test - 5 months ago Dana-Farber spinout Precede exits stealth with blood test technology and $57M - 7 months ago
9	George Budwell Motley Fool Healthcare and science writer. Houston, TX healthcaresciencewriting	1 Biotech Stock That Could Be the Next Amgen - 5 months ago
10	Troy Bremer Pharmacy Times	Expert Discusses Biosignature Model's Potential in Predicting Therapy Response in Early-Stage Breast Cancer - 5 months ago

Journalists covering biomarkers, cancer, clinical test, genetics, genomics, molecular diagnostics, precision medicine, risk variant